Can-Fite BioPharma Ltd. (NYSE: CANF) is an advanced clinical-stage drug development company with a platform technology designed to address multi-billion-dollar markets in the treatment of inflammatory diseases, cancer, and NAFLD/NASH. The company’s lead drug candidate, Piclidenoson, is being evaluated in a global phase 3 trial as a first line therapy for rheumatoid arthritis and a phase 3 trial for moderate-to-severe psoriasis. Can-Fite’s liver cancer drug, CF102, concluded patient enrollment in a phase 2 study for patients with liver cancer, and is slated to enter phase 2 for the treatment of non-alcoholic steatohepatitis. CF102 has shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. For more information, visit the company’s website at www.can-fite.com
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
